Approaches for the design and evaluation of HIV-1 DNA vaccines

References

• Calarota SA, Weiner DB. Present status of human HIV vaccine development. AIDS 17\(Suppl. 4), S73—S84 (2003).
   Google Scholar
• Desrosiers RC. Prospects for an AIDS vaccine. Nature Med10(3), 221–223 (2004).
   Google Scholar
• Wang B, Ugen KE, Srikantan V et al Gene inoculation generates immune responses against human immunodeficiency virus Type 1. Proc. Nati Acad. Sci. USA 90(9), 4156–4160 (1993).
   Google Scholar
• Haynes JR, Fuller DH, Eisenbraun MD, Ford MJ, Pertmer TM. Accele particle-mediated DNA immunization elicits humoral, cytotoxic and protective responses. AIDS Res. Hum. Retroviruses 10 (Suppl. 2), S43—S45 (1994).
   Google Scholar
• Wang B, Merva M, Dang K et al. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells. AIDS Res. Hum. Retroviruses 10 (Suppl. 2), S35—S41 (1994).
   Google Scholar
• Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL. Use of DNAs expressing HIV-1 env and non-infectious HIV-1 particles to raise antibody responses in mice. Virology209(1), 147–154 (1995).
   Google Scholar
• Yasutomi Y, Robinson HL, Lu S et al Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys.j Viral. 70(1), 678–681 (1996).
   Google Scholar
• Boyer JD, Ugen KE, Wang B et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3 (5), 526–532 (1997).
   Google Scholar
• Letvin NL, Montefiori DC, Yasutomi Y et al Potent, protective antiHR/ immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Nati Acad. Sci. USA 94(17), 9378–9383 (1997).
   Google Scholar
• MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus Type 1 infection: safety and host response. j Infect. Dis. 178(1), 92–100 (1998).
   Google Scholar
• Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351(9112), 1320–1325 (1998).
   Google Scholar
• Calarota SA, Leandersson AC, Bratt G et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. immund 163(4), 2330–2338 (1999).
   Google Scholar
• Boyer JD, Chattergoon MA, Ugen KE et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Gun. Immunol 90(1), 100–107 (1999).
   Google Scholar
• Calarota SA, Kjerrström A, Islam KB, Wahren B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Human Gene Therapy 12(13), 1623–1637 (2001).
   Google Scholar
• Boyer JD, Cohen AD, Vogt S et al. Vaccination of seronegative volunteers with a human immunodeficiency virus Type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of P-chemokines. J. Infect. Dis. 181(2), 476–483 (2000).
   Google Scholar
• Ayyavoo V, Kudchodkar S, Ramanathan MP et al. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes. AIDS14 (1), 1–9 (2000).
   Google Scholar
• Kjerrström A, Hinkula J, Engstrom G et aL Interactions of single and combined human immunodeficiency virus type 1 DNA vaccines. Virology 284 (1), 46–61 (2001).
   Google Scholar
• Muthumani K, Bagarazzi M, Conway D et al Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivoresulting in CD4 cell loss and increased viral loads in rhesus macaques. j Med. Primatol. 31(4–5), 179–185 (2002).
   Google Scholar
• Ensoli B, Cafaro A. HIV-1 Tat vaccines. Virus Res. 82(1–2), 91–101 (2002).
   Google Scholar
• Cafaro A, Titti F, Fracasso C et al. Vaccination with DNA containing tat encoding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19(20–22), 2862–2877 (2001).
   Google Scholar
• Allen TM, Mortara L, Mothe BR et al. Tat- vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. j Viral. 76(8), 4108–4112 (2002).
   Google Scholar
• Allen TM, O'Connor D, Jing P et al. Tat- specific cytotoxic T-lymphocytes select for SW escape variants during resolution of primary viraemia. Nature 407(6802), 386–390 (2000).
   PubMed Web of Science ®Google Scholar
• Smith SM, Pentlicky S, Klase Z et al An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T-lymphocyte selection. J. Biol. Chem. 278(45), 44816–44825 (2003).
   Google Scholar
• Gruters RA, van Baalen CA, Osterhaus ADME. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes . Vaccine 20 (15), 2011–2015 (2002).
   PubMed Web of Science ®Google Scholar
• Sheehy AM, Gaddis NC, Choi JD, Malim MET. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898), 646–650 (2002).
   Google Scholar
• Ayyavoo V, Nagashunmugam T, Phung MT et al. Construction of attenuated HIV-1 accessory gene immunization cassettes. Vaccine 16(19), 1872–1879 (1998).
   Google Scholar
• Tungaturthi PK, Sawaya BE, Singh SP et al Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Domed Pharmacother. 57(1), 20–24 (2003).
   Google Scholar
• Muthumani K, Choo AY, Hwang DS et al. Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem. Biophys. Res. Commun. 304(3), 583–592 (2003).
   Google Scholar
• Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. Cytotoxic T-lymphocytes (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol. 21(9), 671–678 (2002).
   Google Scholar
• Muthumani K, Hwang DS, Dayes NS, Kim JJ, Weiner DB. The HIV-1 accessory gene vpr can inhibit antigen-specific immune function. DNA Cell Biol. 21(9), 689–695 (2002).
   Google Scholar
• Muthumani K, Kudchodkar S, Zhang D etal. Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine 20(15), 1999-2003 (2002).
   Google Scholar
• Bour S, Strebel K. The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect. 5 (11), 1029–1039 (2003).
   Google Scholar
• Betts MR, Ambrozak DR, Douek DC etal. Analysis of total human immunodeficiency virus (HIV)-sepcific CD4+ and CD8* T-cell responses: relationship to viral load in untreated HIV infection. j Viral 75(24), 11983–11991 (2001).
   Google Scholar
• Addo MM, Yu XG, Rathod A et al. Comprehensive epitope analysis of human immunodeficiency virus Type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but not correlation to viral load. j Viral 77(3), 2081-2093 (2003).
   Google Scholar
• Zur Megede J, Chen MC, Doe B et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus Type 1 gag gene. Viral 74(6), 2628–2635 (2000).
   Google Scholar
• Bojak A, Wild J, Deml L, Wagner R. Impact of codon usage modification on T-cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines. Intervirology 45 (4–6), 275–286 (2002).
   Google Scholar
• Qiu JT, Liu B, 'Dan C, Pavlakis GN, Yu XF. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus Type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. Viral 74(13), 5997–6005 (2000).
   Google Scholar
• Huang Y, Kong WP, Nabel GJ. Human immunodeficiency virus Type 1-specific immunity after genetic immunization is enhanced by modification of gag and pol expression. Viral 75(10), 4947–4951 (2001).
   Google Scholar
• Egan MA, Charini WA, Kuroda MJ et al. Simian immunodeficiency virus (SW) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SW infection. j Vim!. 74(16), 7485–7495 (2000).
   Google Scholar
• Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869), 331–335 (2002).
   PubMed Web of Science ®Google Scholar
• Wee EGT, Patel S, McMichael AJ, Hanke T A DNA/MVA-based candidate HIV vaccine for Kenya induces multi-specific T-cell responses in rhesus macaques. j Gem Viral 83(Pt 1), 75–80 (2002).
   Google Scholar
• Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. j Gen. Viral 85\(Pt 4), 911–919 (2004).
   Google Scholar
• Haas G, Samri E, Gomard E et al. Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. AIDS 12(12), 1427–1436 (1998).
   Google Scholar
• Betts MR, Krowka J, Santamaria C et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. Viral 71(11), 8908–8911 (1997).
   Google Scholar
• Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T-cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. j Clin. Invest. 102(9), 1758–1765 (1998).
   Google Scholar
• Bagarazzi ML, Boyer JD, Javadian MA et al. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus Type 1 DNA plasmid vaccines to pregnant chimpanzees. Infect. Dis. 180(4), 1351–1355 (1999).
   Google Scholar
• Casimiro DR, Tang A, Perry HC et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus Type 1 po/gene. j Vim!. 76(1), 185–194 (2002).
   Google Scholar
• Tabernero C, Zolotukhin AS, Valentin A, Pavlakis GN, Felber BK. The posttranscriptional control element of the simian retrovirus Type 1 forms an extensive RNA secondary structure necessary for its function. j Viral 70(9), 5998–6011 (1996).
   Google Scholar
• Zur Megede J, Often GR, Doe B et al. Expression and immunogenicity of sequence-modified human immunodeficiency virus Type 1 subtype B pol and gagpol DNA vaccines. j Viral 77 (11), 6197–6207 (2003).
   Google Scholar
• Muthumani K, Bagarazzi M, Conway et al. A Gag-Pol/Env-Rev 5IV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIVmac251 challenge in rhesus macaques. Vaccine 21(7–8), 629–637 (2003).
   Google Scholar
• Burton DR, Desrosiers RC, Doms RVV et al. HIV vaccine design and the neutralizing antibody problem. Nature Immunol 5(3), 233–236 (2004).
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD et al. Control of mucosal challenge and prevention of AIDS by a multi-protein DNA/MVA vaccine. Science 292(5514), 69–74 (2001).
   PubMed Web of Science ®Google Scholar
• Amara RR, Smith JM, Staprans SI et al. Critical role for env as well as gag-pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76(12), 6138–6146 (2002).
   Google Scholar
• Doria-Rose NA, Ohlen C, Polacino P et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4* — T-cell depletion after simian—human immunodeficiency virus 5HIV89.6P mucosal challenge. j Vim!. 77(21), 11563–11577 (2003).
   Google Scholar
• Cherpelis S, Shrivastava I, Gettie A et al. DNA vaccination with the human immunodeficiency virus Type 1 5F162_V2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques. j Viral 75(3), 1547–1550 (2001).
   Google Scholar
• Gzyl J, Bolesta E, Wierzbicki A et al Effect of partial and complete variable loop deletions of the human immunodeficiency virus Type 1 envelope glycoprotein on the breath of gp160-specific immune responses. Virology318(2), 493–506 (2004).
   Google Scholar
• Chakrabarti BK, Kong W, Wu B et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. j Viral 76(11), 5357–5368 (2002).
   Google Scholar
• Muthumani K, Zhang D, Dayes NS et al. Novel engineered HIV-1 East African clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology314(1), 134–146 (2003).
   Google Scholar
• Gaschen B, Taylor J, Yusim K et al. Diversity considerations in HIV-1 vaccine selection. Science 296(5577), 2354–2360 (2002).
   Google Scholar
• Nickle DC, Jensen MA, Gottlieb GD, Shiner D, Learn GH, Rodrigo AG, Mullins JI. Consensus and ancestral state HR/ vaccine. Science 299(5612), 1515–1517 (2003).
   Google Scholar
• Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302 (1), 44–57 (2002).
   Google Scholar
• Kim JJ, Nottingham K, Tsai A etal. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the used of IFN-y, IL-12, or IL-18 gene adjuvants. Merl Primatol. 28(4–5), 214–223 (1999).
   Google Scholar
• Kim JJ, Yang JS, Montaner L, Lee DJ, Chalian AA, Weiner DB. Coimmununization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Thl -type DNA vaccine induced immune responses in vivo. j Interferon Cytokine Res. 20(3), 311–319 (2000).
   Google Scholar
• Kim JJ, Yang JS, vanCott TC et al. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. Viral 74(7), 3427–3429 (2000).
   Google Scholar
• Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-y, or IL-4 gene adjuvants. Vaccine 19(17–19), 2496–2505 (2001).
   Google Scholar
• Kim JJ, Trivedi NN, Nottingham LK etal. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. j Immunol. 28 (3), 1089–1103 (1998).
   Google Scholar
• Barouch DH, Santra S, Steenbeke TD et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. Immunol 161(4), 1875–1882 (1998).
   Google Scholar
• Barouch DH, Craiu A, Kuroda MJ et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl Acad. Sci. USA 97(8), 4192–4197 (2000).
   Google Scholar
• Barouch DH, Santra S, Scmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (5491), 486–492 (2000).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS vaccine failure in a rhesus monkey by the viral escape from cytotoxic T-lymphocytes. Nature 415(6869), 335–339 (2002).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kunstman J, Glowczwskie J et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys. j Viral 77(13), 7367–7375 (2003).
   Google Scholar
• Kim JJ, Ayyavoo V, Bagarazzi ML etal. In viva engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. Immunol 158(2), 816–826 (1997).
   Google Scholar
• Okada E, Sasaki S, Ishli N et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF) -expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. Immunol 159(7), 3638–3647 (1997).
   Google Scholar
• Liu LJ, Watabe S, Yang J et al. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. Vaccine 20(1-2), 42–48 (2002).
   Google Scholar
• Moore AC, Kong W Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. j Viral 76(1), 243–250 (2002).
   PubMed Web of Science ®Google Scholar
• Tsuji T et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. Immunol 158(8), 4008–4013 (1997).
   Google Scholar
• Kim JJ, Maguire HC, Nottingham LK t al. Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Thl phenotype. Interferon Cytokine Res. 18(7), 537–547 (1998).
   Google Scholar
• Boyer JD, Cohen AD, Ugen KE et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. A/DS14(11), 1515–1522 (2000).
   Google Scholar
• Xin KQ, Hamajima K, Sasaki S et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17(7–8), 858–866 (1999).
   Google Scholar
• Billaut-Mulot O, Idziorek T, Ban E et al. Interleukin-18 modulates immune responses induced by HIV-1 nef DNA prime/protein boost vaccine. Vaccine 19 (1), 95–102 (2001).
   Google Scholar
• Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine 19 (20–22), 2803–2811 (2001).
   Google Scholar
• KiM JJ, Bagarazzi ML, Trivedi N et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotechnol 15(7), 641–646 (1997).
   PubMedGoogle Scholar
• Kim JJ, Nottingham LK, Wilson DM etal. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 16(19), 1828–1835 (1998).
   PubMed Web of Science ®Google Scholar
• Tsuji T, Hamajima K, Ishii N etal. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus- 1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur j Immunol 27(3), 782–787 (1997).
   Google Scholar
• Iwasaki A, Stiemholm BJ, Chan AK, Berstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. j Immunol 158(10), 4591–4601 (1997).
   PubMedGoogle Scholar
• Santra S, Barouch DH, Sharpe AH, Letvin NL. B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. Eur. j hilinunol. 30 (9), 2650–2659 (2000).
   Google Scholar
• Agadjanyan MG, Kim JJ, Trivedi N et al. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. Immunol 162(6), 3417–3427 (1999).
   Google Scholar
• Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J. Immunol 160 (12), 5707–5718 (1998).
   PubMed Web of Science ®Google Scholar
• Agadjanyan MG, Chattergoon MA, Holterman MJ et al. Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86. hnmunol. 171(8), 4311–4319 (2003).
   Google Scholar
• Denis-Mize KS, Dupuis M, Singh M et al. Mechanisms of increased immunogenicity for DNA-based vaccines absorbed onto cationic microparticles. Cell. hilinunol. 225(1), 12–20 (2003).
   Google Scholar
• Hamajima K, Kojima Y, Matsui K et al Chitin micro-particles (CIVfP): a useful adjuvant for inducing viral specific immunity when delivered intranasally with an HIV-DNA vaccine. Vital hilinunol. 16(4), 541–547 (2003).
   Google Scholar
• Caulfield MJ, Wang S, Smith JG et al. Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. Vim'. 76(19), 10038–10043 (2002).
   Google Scholar
• Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine22(13–14), 1782–1790 (2004).
   Google Scholar
• Kjerrström Zuber A, Brave A, Engstrom G et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 22(13-14), 1791–1798 (2004).
   Google Scholar
• Gherardi MM, Ramirez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus Type 1 env antigen in a DNA prime/vaccinia virus boost regimen is time and dose-dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J. Viral. 74(14), 6278–6286 (2000).
   Google Scholar
• Barouch DH, McKay PF, Sumida SM et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus Type 1 vaccines. j Vim/. 77(16), 8729–8735 (2003).
   Google Scholar
• O'Neill E, Martinez I, Villinger F et al. Protection by SW VLP DNA Prime/protein boost following mucosal SW challenge is markedly enhanced by IL-12/GM-CSF co-administration. J. Med. Primatol 31(4–5), 217–227 (2002).
   Google Scholar
• O'Neill E, Bastik V, Montefiori DC, Kraiselburd E, Villinger F. IL-12/GM-CSF coadministration in an SW DNA prime/boost protocol enhances gag-specific T-cells but not virus-specific neutralizing antibodies in rhesus macaques. AIDS Res. Human Retivviruses19(10), 883–890 (2003).
   Google Scholar
• Allen TM, Sidney J, del Guercio ME et al. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. hilinunol. 160(12), 6062–6071 (1998).
   Google Scholar
• Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T-cell cytokine expression in whole blood by flow cytometry. j hilinunol. Methods 212(1), 89–98 (1998).
   Google Scholar
• Maecker HT, Dunn HS, Suni MA et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. Immunol Methods 255(1-2), 27–40 (2001).
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Staprans SI et al. Different patterns of immune responses but similar control of simian immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. Viral. 76(15), 7625–7631 (2002).
   Google Scholar
• Calarota SA, Otero M, Hermanstayne K et al. Use of interleukin-15 to enhance interferon-g production by antigen-specific stimulated lymphocytes from rhesus macaques. J. Immunol Methods 279(1–2), 55–67 (2003).
   Google Scholar
• Jennes W, Kestens L, Nixon DF, ShacIdett BL. Enhanced ELISPOT detection of antigen-specific T-cell responses from cryopreserved specimens with the addition of both IL-7 and IL-15 — the Amplispot assay. J. Immunol Methods270(1), 99–108 (2002).
   Google Scholar
• Rininsland FH, Helms T, Assad RJ et al. Granzyme B ELISPOT assay for ex vivo measurements of T-cell immunity. J. Immunol Methods240(1-2), 143–155 (2000).
   Google Scholar
• Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A. The granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. Trans]. Mer1.1 (1), 14 (2003).
   Google Scholar